Last reviewed · How we verify
Avacincaptad Pegol intravitreal solution
Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.
Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent. Used for Treatment of neovascular (wet) age-related macular degeneration.
At a glance
| Generic name | Avacincaptad Pegol intravitreal solution |
|---|---|
| Sponsor | ONL Therapeutics |
| Drug class | anti-VEGF agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to VEGF and preventing its interaction with its receptor, thereby inhibiting angiogenesis and reducing vascular permeability. This mechanism is thought to be beneficial in treating conditions characterized by excessive angiogenesis, such as age-related macular degeneration.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
Common side effects
- conjunctival hemorrhage
- eye pain
- conjunctival hyperemia
Key clinical trials
- A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE1)
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD (PHASE2)
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |